Estrogen receptor (ER; α isoform) is a redox-sensitive transcription factor, and breast cancer co-expression of progesterone receptor (PR) has long been clinically used to signify a functioning ER response pathway [1] and identify breast cancers that are most likely to respond to ER-targeted endocrine therapy [2-4]. This evidence concerns the gene PGR and breast carcinoma.